Abstract
A 68-year-old man with small-cell lung cancer developed anti-collapsin response-mediator protein (CRMP)-5 antibody-related paraneoplastic neurological syndrome (PNS) presenting with ataxia and chorea during treatment with durvalumab. As a result of steroid therapy, anti-CRMP-5 antibodies became negative, hyperintense lesions on brain magnetic resonance imaging disappeared, and neurological symptoms improved. After resuming durvalumab, he became unable to walk due to neurological adverse events (nAEs). There have been no reported cases manifesting PNSs and nAEs as a result of the same immune checkpoint inhibitors (ICIs) administered at different times. Resuming ICIs in patients diagnosed with PNSs should be performed with prudence.
Original language | English |
---|---|
Pages (from-to) | 1009-1014 |
Number of pages | 6 |
Journal | Internal Medicine |
Volume | 63 |
Issue number | 7 |
DOIs | |
State | Published - 2024/03 |
Keywords
- anti-CRMP-5 antibody
- durvalumab
- immune checkpoint inhibitors
- immune-related adverse events
- neurological adverse events
- paraneoplastic neurological syndromes
ASJC Scopus subject areas
- Internal Medicine